[new299]

Separating out Grail allowed the company to take on outside investment, much of which I imagine flowed back to Illumina in the form of sequencing instrument and consumable sales.

The IP that Illumina is using the block the sale of MGI instruments expires in 2024, I put together some notes on this here:

https://41j.com/blog/2021/05/the-next-few-years-in-dna-seque...

There will probably be a drop in sequencing costs at that time, as there are a few players set to build on expiring IP. Singular Genomics (recent IPO) is one of these, they could possibly be on the market earlier than this (by avoiding some of the last IP to expire).

There's no non-commercial exception for patents, so I don't believe patented approaches could be used in clinical trials. But on the scale of clinical trials, Illumina sequencing would not be prohibitively expensive...